Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.

PubWeight™: 1.15‹?› | Rank: Top 10%

🔗 View Article (PMC 1422519)

Published in Ann Surg on June 01, 2002


Rebekah R White1, Wilma E Stanley, Jeffrey L Johnson, Douglas S Tyler, Hilliard F Seigler

Author Affiliations

1: Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

Articles citing this

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer (2004) 1.63

Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36

Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98

Histopathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol (2004) 0.95

Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res (2011) 0.92

To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence? Int J Clin Pract (2014) 0.91

CCR7 mediates directed growth of melanomas towards lymphatics. Microcirculation (2011) 0.85

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. World J Surg Oncol (2013) 0.83

A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg (2012) 0.83

Prediction of melanoma metastasis by the Shields index based on lymphatic vessel density. BMC Cancer (2010) 0.83

Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett (2010) 0.81

Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. Insights Imaging (2013) 0.81

Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol Cancer (2017) 0.75

Malignant Melanoma. Healthcare (Basel) (2013) 0.75

Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J (2010) 0.75

Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation. Front Immunol (2017) 0.75

Impact of gender and primary tumor location on outcome of patients with cutaneous melanoma. J Med Life (2016) 0.75

Tumor Microenvironment on a Chip: The Progress and Future Perspective. Bioengineering (Basel) (2017) 0.75

Articles cited by this

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol (1999) 3.74

Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg (1999) 3.56

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10

Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol (1999) 2.08

Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg (1991) 2.06

Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol (1998) 1.92

Complications and local recurrence following lymphadenectomy. Br J Surg (1990) 1.79

Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA (1998) 1.62

Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer (1997) 1.59

Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res (2001) 1.59

Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol (1999) 1.55

Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol (2001) 1.42

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine (1994) 1.28

Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol (1999) 1.22

Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg (1994) 1.16

Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg (1989) 1.12

Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg (1991) 1.07

Non-specific and specific immunotherapy in patients with melanoma. Surgery (1972) 1.06

Specific active immunotherapy for melanoma. Ann Surg (1979) 1.02

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg (1998) 1.00

The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide. Cancer (1993) 0.99

Active-specific immunotherapy for melanoma. J Clin Oncol (1990) 0.95

Axillary dissection in melanoma. Prognostic variables in node-positive patients. Ann Surg (1990) 0.91

Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol (1988) 0.87

A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer (1986) 0.85

Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann N Y Acad Sci (1993) 0.85

A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. Cancer (1974) 0.79

Prognostic variables for patients with stage III malignant melanoma. Eur J Surg (2000) 0.78

Articles by these authors

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74

A genomic storm in critically injured humans. J Exp Med (2011) 6.67

Disparities in liver transplantation before and after introduction of the MELD score. JAMA (2008) 4.10

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol (2003) 3.00

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60

Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core--standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. J Trauma (2006) 2.57

Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma (2008) 2.52

Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50

Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer (2003) 2.39

Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg (2002) 2.34

Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol (2005) 2.34

Preperitonal pelvic packing for hemodynamically unstable pelvic fractures: a paradigm shift. J Trauma (2007) 2.15

Benchmarking outcomes in the critically injured trauma patient and the effect of implementing standard operating procedures. Ann Surg (2012) 2.07

Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00

Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96

Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography. Ann Surg (2002) 1.94

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91

Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol (2005) 1.88

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2008) 1.83

Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg (2011) 1.82

A 12-year prospective study of postinjury multiple organ failure: has anything changed? Arch Surg (2005) 1.80

Inflammation and the Host Response to Injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care. III. Guidelines for shock resuscitation. J Trauma (2006) 1.78

The practice of venous thromboembolism prophylaxis in the major trauma patient. J Trauma (2007) 1.76

Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle (2008) 1.76

Is emergency department resuscitative thoracotomy futile care for the critically injured patient requiring prehospital cardiopulmonary resuscitation? J Am Coll Surg (2004) 1.76

Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg (2010) 1.75

Inflammation and the Host Response to Injury, a large-scale collaborative project: Patient-Oriented Research Core--standard operating procedures for clinical care. I. Guidelines for mechanical ventilation of the trauma patient. J Trauma (2005) 1.73

The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol (2012) 1.66

HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock (2009) 1.64

Validation of postinjury multiple organ failure scores. Shock (2009) 1.64

Carotid artery stents for blunt cerebrovascular injury: risks exceed benefits. Arch Surg (2005) 1.63

Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol (2006) 1.62

One thousand bedside percutaneous tracheostomies in the surgical intensive care unit: time to change the gold standard. J Am Coll Surg (2010) 1.61

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol (2009) 1.61

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood (2011) 1.55

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol (2003) 1.54

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma (2012) 1.54

The role of the lung in postinjury multiple organ failure. Surgery (2005) 1.54

Inflammation and the host response to injury, a large-scale collaborative project: Patient-oriented research core-standard operating procedures for clinical care. IV. Guidelines for transfusion in the trauma patient. J Trauma (2006) 1.52

Pancreatic duct strictures: identifying risk of malignancy. Ann Surg Oncol (2004) 1.52

Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52

Surgical stabilization of severe rib fractures. J Trauma Acute Care Surg (2015) 1.48

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood (2007) 1.48

Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol (2006) 1.48

Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol (2006) 1.47

The two-event construct of postinjury multiple organ failure. Shock (2005) 1.46

Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery (2009) 1.44

Predicting disease progression after regional therapy for in-transit melanoma. JAMA Surg (2013) 1.44

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44

Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness. N Engl J Med (2002) 1.43

A cost-minimization analysis of phenytoin versus levetiracetam for early seizure pharmacoprophylaxis after traumatic brain injury. J Trauma Acute Care Surg (2012) 1.42

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39

Decreased progression of postinjury lung dysfunction to the acute respiratory distress syndrome and multiple organ failure. Surgery (2006) 1.39

Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core-standard operating procedures for clinical care: VI. Blood glucose control in the critically ill trauma patient. J Trauma (2007) 1.37

Anticoagulation is the gold standard therapy for blunt carotid injuries to reduce stroke rate. Arch Surg (2004) 1.36

Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol (2008) 1.36

Intraoperative radiation therapy. J Clin Oncol (2007) 1.31

Cervical spine fracture patterns predictive of blunt vertebral artery injury. J Trauma (2003) 1.31

Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg (2003) 1.30

Inflammation and the host response to injury, a Large-Scale Collaborative Project: patient-oriented research core standard operating procedures for clinical care IX. Definitions for complications of clinical care of critically injured patients. J Trauma (2009) 1.29

Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28

Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys (2005) 1.28

Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg (2014) 1.26

Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med (2005) 1.26

Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26

NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol (2012) 1.23

One hundred percent fascial approximation with sequential abdominal closure of the open abdomen. Am J Surg (2006) 1.22

Noninvasive diagnosis of blunt cerebrovascular injuries: a preliminary report. J Trauma (2002) 1.22

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21

Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients. J Trauma (2008) 1.21

Inflammation and the host response to injury a large-scale collaborative project: patient-oriented research core standard operating procedure for clinical care X. Guidelines for venous thromboembolism prophylaxis in the trauma patient. J Trauma (2008) 1.20

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer (2004) 1.18

Presence of the M-type sPLA(2) receptor on neutrophils and its role in elastase release and adhesion. Am J Physiol Cell Physiol (2002) 1.16

Temporal trends of postinjury multiple-organ failure: still resource intensive, morbid, and lethal. J Trauma Acute Care Surg (2014) 1.11

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res (2008) 1.11

Transfusion of the injured patient: proceed with caution. Shock (2004) 1.11

Blunt cerebrovascular injuries: redefining screening criteria in the era of noninvasive diagnosis. J Trauma Acute Care Surg (2012) 1.10

Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.10

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther (2010) 1.08

Treatment for blunt cerebrovascular injuries: equivalence of anticoagulation and antiplatelet agents. Arch Surg (2009) 1.08

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery (2003) 1.08

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma (2007) 1.08

Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy. Transfusion (2011) 1.08

Cervical spine fracture patterns mandating screening to rule out blunt cerebrovascular injury. Surgery (2006) 1.08

Multiple organ dysfunction during resuscitation is not postinjury multiple organ failure. Arch Surg (2004) 1.07

Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays. Ann Surg (2016) 1.07

Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol (2011) 1.07

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol (2014) 1.07

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer (2012) 1.06

Oncolytic polio virotherapy of cancer. Cancer (2014) 1.05

Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood (2007) 1.05

Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03

The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. J Surg Oncol (2006) 1.02